Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05187182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05187182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2023
Completion date
April 30, 2029
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophagus cancer, gastric cancer, gastroesophageal junction cancer, stomach cancer